Sandoz, a Novartis division and a global leader in biosimilars, announced that the United States District Court of New Jersey ruled against Sandoz in patent litigation concerning the Sandoz biosimilar, Erelzi (etanercept-szzs) for reference medicine Enbrel (etanercept). The company will appeal the ruling to the US Court of Appeals for the Federal Circuit, and the parties have agreed to an expedited appeal.
Chemical Name |
Synonyms |
Molecular Formula |
Molecular Weight |
---|
Product Name | Innovator |
---|
Product Name | Market Status |
---|
Product Name | Indication |
---|
Product Name | Therapeutic Segment |
---|
Your product will be updated soon in our database